Raloxifene therapy in the reduction of fractures.
Cefalu
C A
CA
D000368:Aged; D001779:Blood Coagulation Factors / Q000378:metabolism; D015519:Bone Density / Q000187:drug effects; D001943:Breast Neoplasms / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000150:complications* / Q000188:drug therapy*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D016896:Treatment Outcome
D001779:Blood Coagulation Factors; D020847:Estrogen Receptor Modulators; D008055:Lipids; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride